What Spooked Eyegate Pharmaceuticals Inc Investors Today

Shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) dropped by as much as 47% in early trading Monday. The reason? The stock’s double-digit nosedive was sparked by disappointing top-line results from a phase 2b trial of the company’s EGP-437 combination product for pain and inflammation in patients having undergone cataract surgery.

Read more: This biotech stock portfolio has tripled the IBB since inception

Eyegate reported that the co-primary endpoints of proportion of subjects with an anterior chamber cell (ACC) count of zero at day 7 and the proportion of subjects with a pain score of zero at day 1 did not show statistical significance. However, the trial did demonstrate a higher rate of success compared to vehicle at all time points.

“The efficacy results for the absence of inflammatory cells in the EGP-437 treatment group met our expectations, but the vehicle group response was better than anticipated. The magnitude of reduction for EGP-437 compares favorably with the historical data from studies of other anti-inflammatory products, which we believe is an encouraging sign,” said Randall Olson MD, strategic advisor to EyeGate.

The double-masked, randomized, vehicle-controlled Phase 2b study enrolled 106 subjects at seven U.S. clinical sites. The trial evaluated the safety and efficacy of trans-scleral iontophoretically-delivered EGP-437, dexamethasone, through the Company’s EyeGate® II Delivery System in patients that have previously undergone cataract surgery with implantation of a monofocal posterior chamber IOL, starting immediately after surgery.

EGP-437 showed numerically better clinical efficacy, defined as an ACC count of zero, throughout the study, especially at Day 14 and beyond. At a majority of timepoints, a greater number of subjects in the EGP-437 arm achieved a pain score of zero compared to control. For the secondary endpoints, based on change in mean cell count and change in mean pain score, EGP-437 showed statistically significant improvements in both ACC count and pain score, on Day 7 and Day 1 respectively. In addition, the EGP-437 arm demonstrated a favorable safety profile with no serious adverse events reported.

“We will continue to review the data to determine next steps and to continue evaluating EGP-437 for the reduction of pain and inflammation following ocular surgery,” said Barbara Wirostko MD, Chief Medical Officer of EyeGate.

On the ratings front, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on EYEG, with a price target of $5.00, in a report issued on December 19. The current price target implies an upside of 747% from current levels. According to TipRanks.com, Selvaraju has a yearly average loss of 11.1%, a 32% success rate, and is ranked #4702 out of 4745 analysts.

EyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its products include EGP-437 and EyeGate II Delivery System. EGP-437 treat non-infectious anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris or ciliary body. The EyeGate II Delivery System delivers drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts